AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7815310 — intervention group
Group type: EXPERIMENTAL
Intervention: rec-hirudin (all doses)
Number of subjects: 77
Study 2544829 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone
Number of subjects: 61
Study 2544829 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ACTH
Number of subjects: 61
Study 31066313 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring with mentors with visual impairment (N=25)
Number of subjects: 76
Study 31066313 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring with mentors without visual impairment (N=26)
Number of subjects: 76
Study 31066313 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (N=25)
Number of subjects: 76
Study 30624555 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28702806 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib plus Docetaxel
Number of subjects: 0
Study 25342652 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapies (EVTs)
Number of subjects: 200
Study 22982425 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic studies after office evaluation
Number of subjects: 294
Study 21986208 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) with conditioning from common peroneal nerve (CPN) at CT intervals of 35 ms and 50-55 ms.
Number of subjects: 0
Study 21986208 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the posterior tibial nerve (PTN) to activate H-reflexes.
Number of subjects: 0
Study 21986208 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold TMS pulse with CPN stimulation at CT intervals of 40-45 ms.
Number of subjects: 0
Study 21986208 — intervention group
Group type: EXPERIMENTAL
Intervention: CPN stimulation prior to dorsiflexion.
Number of subjects: 0
Study 18687539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (1.25 mg/day women's equivalent)
Number of subjects: 18
Study 18687539 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy + Tibolone (138 mg isoflavones/day women's equivalent)
Number of subjects: 18
Study 18687539 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy (52 g of soy protein containing 112 mg isoflavones)
Number of subjects: 18
Study 18687539 — intervention group
Group type: COMPARATOR
Intervention: Placebo (52 g of milk protein)
Number of subjects: 18
Study 16822116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 108
Study 16822116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 16822116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) plus fluoxetine
Number of subjects: 108
Study 16822116 — intervention group
Group type: COMPARATOR
Intervention: CBT plus placebo
Number of subjects: 108
Study 12566778 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1) gel administered in the ambulatory form (group 1)
Number of subjects: 89
Study 12566778 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1) gel administered in the labor room (group 2)
Number of subjects: 89
Study 12566778 — intervention group
Group type: COMPARATOR
Intervention: Intravenously administered oxytocin (group 3)
Number of subjects: 89
Study 10871006 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel size of 0.95 x 0.76 x 0.82 mm (group 2)
Number of subjects: 44
Study 10871006 — intervention group
Group type: COMPARATOR
Intervention: Voxel size of 1.3 x 1.29 x 1.25 mm (group 1)
Number of subjects: 44
Study 10871006 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resolution technique
Number of subjects: 44
Study 10871006 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution technique
Number of subjects: 44
Study 9198048 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency haemodialysis (dialyser blood flow rate = 400 ml/min; dialysis time = 170.67 min)
Number of subjects: 6
Study 9198048 — intervention group
Group type: COMPARATOR
Intervention: Standard haemodialysis (dialyser blood flow rate = 200 ml/min; dialysis time = 240 min)
Number of subjects: 6
Study 8475871 — intervention group
Group type: EXPERIMENTAL
Intervention: New York Heart Association class I patients
Number of subjects: 308
Study 8475871 — intervention group
Group type: COMPARATOR
Intervention: New York Heart Association class II or III patients
Number of subjects: 308
Study 2580678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of amino acids (100 ml/hr 10%)
Number of subjects: 31
Study 2580678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of fat (100 ml/hr 10%)
Number of subjects: 31
Study 2580678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of glucose (150 ml/hr 10%)
Number of subjects: 31
Study 2580678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of higher glucose dose (100 ml 20% glucose as a bolus followed by 300 ml/hr 10%)
Number of subjects: 31
Study 2580678 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 31
Study 30006299 — intervention group
Group type: EXPERIMENTAL
Intervention: Caprylidene
Number of subjects: 16
Study 30006299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27423055 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately intense glucose control
Number of subjects: 60
Study 27423055 — intervention group
Group type: COMPARATOR
Intervention: Standard control
Number of subjects: 60
Study 24332139 — intervention group
Group type: EXPERIMENTAL
Intervention: CVAR assessment by trained family physicians with an electronic CVAR calculator
Number of subjects: 1074
Study 24332139 — intervention group
Group type: COMPARATOR
Intervention: General health check (Control)
Number of subjects: 1074
Study 23095609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection device
Number of subjects: 101
Study 23095609 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection
Number of subjects: 101
Study 19422632 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support and counselling 2 and 10 weeks after surgery
Number of subjects: 180
Study 19422632 — intervention group
Group type: COMPARATOR
Intervention: Conventional care and treatment (Control)
Number of subjects: 180
Study 17660006 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate in alcohol
Number of subjects: 36
Study 17660006 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine povacrylex in alcohol
Number of subjects: 36
Study 16280002 — intervention group
Group type: EXPERIMENTAL
Intervention: DISKHALER dry powder inhaler
Number of subjects: 0
Study 16280002 — intervention group
Group type: COMPARATOR
Intervention: ROTAHALER dry powder inhaler
Number of subjects: 0
Study 12212977 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected group (no half-mask)
Number of subjects: 33
Study 12212977 — intervention group
Group type: COMPARATOR
Intervention: Half-mask group
Number of subjects: 33
Study 10441861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of trometamol salt of thioctic (alpha-lipoic) acid (Thioctacid 600) in 200 ml of physiological solution
Number of subjects: 40
Study 10441861 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological solution stained with 1% solution of riboflavin mononucleate)
Number of subjects: 40
Study 7794850 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg oestradiol implants
Number of subjects: 32
Study 7794850 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 women)
Number of subjects: 32
Study 2217893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular P (group B)
Number of subjects: 30
Study 2217893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular P and hCG (group C)
Number of subjects: 30
Study 2217893 — intervention group
Group type: COMPARATOR
Intervention: No support (group A)
Number of subjects: 30
Study 2217893 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (intramuscular P and hCG)
Number of subjects: 30
Study 2217893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant cycles
Number of subjects: 30
Study 789186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 200
Study 789186 — intervention group
Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 200
Study 30020511 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRVB)
Number of subjects: 342
Study 30020511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for Interpretation (CBM-I)
Number of subjects: 342
Study 30020511 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 342
Study 29296811 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson (1.44 μg/kg per hour)
Number of subjects: 92
Study 29296811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 29296811 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 92
Study 25574111 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-based triple therapy (PAC group: rabeprazole, amoxicillin, clarithromycin)
Number of subjects: 680
Study 25574111 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole-based triple therapy (PAM group: rabeprazole, amoxicillin, metronidazole)
Number of subjects: 680
Study 25574111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (rabeprazole and amoxicillin followed by rabeprazole, clarithromycin and metronidazole)
Number of subjects: 680
Study 25574111 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (rabeprazole, amoxicillin, clarithromycin and metronidazole)
Number of subjects: 680
Study 23548622 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival sirolimus (440 μg) administered every 3 months for 24 months
Number of subjects: 11
Study 23548622 — intervention group
Group type: COMPARATOR
Intervention: Fellow eyes (untreated controls)
Number of subjects: 11
Study 21972580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified mouth care protocol (6 sessions per day including 2 teeth brushings and 4 sessions with chlorhexidine 0.12%)
Number of subjects: 182
Study 21972580 — intervention group
Group type: COMPARATOR
Intervention: Standard mouth care protocol (3 sessions per day including chlorhexidine 0.12%)
Number of subjects: 182
Study 21972580 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified mouth care protocol
Number of subjects: 182
Study 19834019 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplasmin 2 mg/kg
Number of subjects: 40
Study 19834019 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplasmin 3 mg/kg
Number of subjects: 40
Study 19834019 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplasmin 4 mg/kg
Number of subjects: 40
Study 19834019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16675781 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg)
Number of subjects: 336
Study 16675781 — intervention group
Group type: COMPARATOR
Intervention: Ethambutol
Number of subjects: 336
Study 16675781 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 336
Study 14726080 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 40
Study 14726080 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 40
Study 11041197 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral slide exercise incorporated into home exercise program
Number of subjects: 14
Study 11041197 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lateral slide exercise)
Number of subjects: 14
Study 11041197 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (lateral slide exercise and control)
Number of subjects: 14
Study 9250760 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) coating
Number of subjects: 15
Study 9250760 — intervention group
Group type: COMPARATOR
Intervention: Fluorapatite (FA) coating
Number of subjects: 15
Study 9250760 — intervention group
Group type: EXPERIMENTAL
Intervention: Both coatings
Number of subjects: 15
Study 8350466 — intervention group
Group type: COMPARATOR
Intervention: 0 gamma of PGE1
Number of subjects: 36
Study 8350466 — intervention group
Group type: COMPARATOR
Intervention: 0.005 gamma of PGE1
Number of subjects: 36
Study 8350466 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 gamma of PGE1
Number of subjects: 36
Study 3551606 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 10
Study 3551606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30348113 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 14
Study 30348113 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 27080806 — intervention group
Group type: EXPERIMENTAL
Intervention: Play distraction (storytelling, pictures, and colouring activities)
Number of subjects: 168
Study 27080806 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological premedication
Number of subjects: 168
Study 24929548 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted oral debriefing (VAOD)
Number of subjects: 48
Study 24929548 — intervention group
Group type: COMPARATOR
Intervention: Oral debriefing alone (ODA)
Number of subjects: 48
Study 22037722 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical suspension of bacterial antigens (Lantigen B)
Number of subjects: 210
Study 22037722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 20338560 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy treatment on days 8 or/and 11 to 13 of the menstrual cycle
Number of subjects: 0
Study 20338560 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy treatment
Number of subjects: 0
Study 20338560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biopsy treatment)
Number of subjects: 0
Study 18669897 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinal statistical tests (e.g., bootstrapping the difference in mean rank, Mann‐Whitney U test, ordinal logistic regression)
Number of subjects: 335305
Study 18669897 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinal statistical tests
Number of subjects: 335305
Study 15866563 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (higher dose)
Number of subjects: 0
Study 15866563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12784833 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed forgetting task with instructions to remember or forget neutral and emotional words.
Number of subjects: 12
Study 12784833 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit memory assessment across states.
Number of subjects: 12
Study 12784833 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory recall assessment for emotional vs neutral information.
Number of subjects: 12
Study 10505914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ottawa ankle rules
Number of subjects: 761
Study 10505914 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical)
Number of subjects: 761
Study 8721637 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography (5 to 10 microg/kg/min)
Number of subjects: 45
Study 8721637 — intervention group
Group type: COMPARATOR
Intervention: Thallium-201 SPECT with reinjection
Number of subjects: 45
Study 1781563 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.4 mg/kg)
Number of subjects: 90
Study 1781563 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal midazolam (0.5 mg/kg)
Number of subjects: 90
Study 1781563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal midazolam (0.2 mg/kg)
Number of subjects: 90
Study 6764827 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccinated group
Number of subjects: 54239
Study 6764827 — intervention group
Group type: EXPERIMENTAL
Intervention: vole‐bacillus vaccinated group
Number of subjects: 54239
Study 6764827 — intervention group
Group type: COMPARATOR
Intervention: randomly‐allocated unvaccinated (control) group
Number of subjects: 54239
Study 31903505 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear aligners (Invisalign)
Number of subjects: 70
Study 31903505 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliances (Victory Series)
Number of subjects: 70
Study 30727929 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal compound (one sachet twice daily for 12 weeks) containing 300 mg Aloe vera, 1.8 g black seed, 300 mg garlic, 2.5 g fenugreek seed, 1 g psyllium seed, 500 mg milk thistle seed
Number of subjects: 50
Study 30727929 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with hypolipidemic and hypoglycemic drugs
Number of subjects: 50
Study 27908974 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor therapy program
Number of subjects: 306
Study 27908974 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 306
Study 25295681 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0
Study 25295681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (CT) with selected nutraceuticals
Number of subjects: 0
Study 25295681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22849318 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental cheese (from cows fed a grass and maize silage‐based diet with 5% of linseed oil added)
Number of subjects: 0
Study 22849318 — intervention group
Group type: COMPARATOR
Intervention: Control cheese (without linseed oil)
Number of subjects: 0
Study 21658122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking (5 hours per week for 4 months)
Number of subjects: 212
Study 21658122 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained unaltered habitual lifestyle)
Number of subjects: 212
Study 21658122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking
Number of subjects: 212
Study 21658122 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 212
Study 19458434 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cranioplasty
Number of subjects: 26
Study 19458434 — intervention group
Group type: EXPERIMENTAL
Intervention: Late cranioplasty
Number of subjects: 26
Study 19458434 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (reference standard)
Number of subjects: 26
Study 16737369 — intervention group
Group type: EXPERIMENTAL
Intervention: Social category primes
Number of subjects: 0
Study 16737369 — intervention group
Group type: COMPARATOR
Intervention: Response behavior primes
Number of subjects: 0
Study 16737369 — intervention group
Group type: EXPERIMENTAL
Intervention: Social category primes with differentiation mind-set
Number of subjects: 0
Study 16737369 — intervention group
Group type: COMPARATOR
Intervention: Social category primes with similarity mind-set
Number of subjects: 0
Study 14962397 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory suppression condition
Number of subjects: 0
Study 14962397 — intervention group
Group type: COMPARATOR
Intervention: Control (no dual-task) condition
Number of subjects: 0
Study 11701403 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane encasings impermeable to particles > 3 mum
Number of subjects: 0
Study 11701403 — intervention group
Group type: COMPARATOR
Intervention: Conventional cotton encasings
Number of subjects: 0
Study 9002118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 10 mg/kg every 8 h for 7 days followed by oral ciprofloxacin 20 mg/kg every 12 h for a minimum of 3 days
Number of subjects: 130
Study 9002118 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 50 mg/kg every 8 h plus tobramycin 3 mg/kg every 8 h for a minimum of 10 days
Number of subjects: 130
Study 9002118 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (ciprofloxacin and ceftazidime/tobramycin)
Number of subjects: 130
Study 8299664 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 20 mg
Number of subjects: 10
Study 8299664 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 10
Study 8299664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg
Number of subjects: 10
Study 8299664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 10
Study 8299664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2436183 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cerebellar stimulation (CCS) using the Neurolith 601 stimulator, with ON-OFF switching controlled by a magnetically controllable switch, duration of stimulation was four months after surgery.
Number of subjects: 33
Study 2436183 — intervention group
Group type: COMPARATOR
Intervention: Chronic cerebellar stimulation (CCS)
Number of subjects: 33
Study 30043517 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 0
Study 26454361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg once a week
Number of subjects: 380
Study 26454361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 380
Study 26454361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 380
Study 26454361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks
Number of subjects: 380
Study 26454361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 100 mg every 4 weeks
Number of subjects: 380
Study 26454361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 25605628 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhiatal (TH) approach
Number of subjects: 167
Study 25605628 — intervention group
Group type: COMPARATOR
Intervention: Left thoracoabdominal (LTA) approach
Number of subjects: 167
Study 23580011 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oral contraceptives (OCs) therapy with different progestins (desogestrel, gestodene, dienogest)
Number of subjects: 168
Study 23580011 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who refused postoperative hormonal therapy)
Number of subjects: 168
Study 20307355 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g alpha-lactalbumin (LAC; l-tryptophan (Trp):large neutral amino acids (LNAA) ratio of 7.6)
Number of subjects: 25